Catalysts / COGT
Upcoming FDA decisions and readouts we track for Cogent Biosciences, each with the filing that announced it.
FreeBioList tracks 2 upcoming catalysts for Cogent Biosciences (COGT, listed on Nasdaq). Both concern Bezuclastinib (Gastrointestinal stromal tumour (GIST); Non-advanced systemic mastocytosis).
First on the list: the PDUFA date for Bezuclastinib (Gastrointestinal stromal tumour (GIST)), dated 30 Nov 2026. By stage, the upcoming rows are 2 PDUFA dates.
Both rows link to SEC filings (8-K or 6-K). Both have been verified by a person reading the filing itself, most recently on 11 Sep 2026. The methodology page explains each status.
Background reading: What a PDUFA date is, and why the FDA doesn't publish them.
| Company ▾ | Drug ▾ | Effect / indication | Next catalyst ▾ | Phase / type ▾ | Status ▾ | Source | Options |
|---|---|---|---|---|---|---|---|
| Cogent Biosciences COGT · Nasdaq | Bezuclastinib | Gastrointestinal stromal tumour (GIST) | 30 Nov 2026 in 54d |
PDUFA date | Verified | 8-K exhibit 99.1 ↗ | Yes |
| Cogent Biosciences COGT · Nasdaq | Bezuclastinib | Non-advanced systemic mastocytosis | 30 Dec 2026 in 84d |
PDUFA date | Verified | 8-K exhibit 99.1 ↗ | Yes |
FreeBioList